ARKG's Sharpe Ratio of 1.75 indicates that for each unit of volatility, it generates 1.75 units of excess return above the risk-free rate. The ratio is calculated using historical daily returns over the past 12 months (as of Jul 8, 2026).
Sharpe uses total volatility (standard deviation) which includes both upside and downside price movements, making it useful for comparing risk-adjusted returns across different assets. For how to read this number and when it can mislead, see Sharpe Ratio Explained.
ARKG Sharpe Ratio Rank
ARKG ranks above 63.6% of all investments in our database based on Sharpe Ratio over the past 12 months, indicating above-average returns relative to volatility. Securities are ranked from 0 (worst) to 100 (best).
What moves the rank
- Strong returns with low total volatility → Higher rank
- High volatility (both upside and downside) → Lower rank
- Consistent returns → Higher rank than volatile returns of same magnitude
- Sharp drawdowns increase volatility → Lower rank
What you can do with this information
- Above-average risk-adjusted returns with room for improvement
- Compare against category peers to gauge relative positioning
- Monitor for movement toward top tier or decline toward median
- Consider pairing with top-tier holdings to improve portfolio efficiency
ARKG Sharpe Ratio Market Positioning
The chart shows ARKG's Sharpe Ratio relative to all ETFs on our platform, with color zones indicating percentile rankings. Higher ratios indicate better risk-adjusted returns.
- Red zone (bottom 25%): 0.82 or lower
- Yellow zone (middle 50%): 0.82 to 1.96
- Green zone (top 25%): 1.96 or higher
- Top 1%: 6.57+
- Median: 1.45 — half of all investments score higher
How it compares to other similar ETFs
The table compares ARK Genomic Revolution Multi-Sector ETF's Sharpe Ratio with other ETFs in the Health & Biotech Equities, Actively Managed category across multiple time periods, showing how ARKG's risk-adjusted performance compares to similar funds.
Data shows 1-, 5-, and 10-year periods, plus each fund's all-time average, as of Jul 8, 2026.
| Symbol | Name | 1Y Sharpe Ratio | 5Y Sharpe Ratio | 10Y Sharpe Ratio | All Time Sharpe Ratio |
|---|---|---|---|---|---|
| BBC | Virtus LifeSci Biotech Clinical Trials ETF | 4.88 | |||
| ABI | VictoryShares Pioneer Asset-Based Income ETF | 4.12 | |||
| SBIO | ALPS Medical Breakthroughs ETF | 4.05 | |||
| XBI | SPDR S&P Biotech ETF | 3.66 | |||
| LFSC | F/m Emerald Life Sciences Innovation ETF | 3.36 | |||
| IHE | iShares U.S. Pharmaceuticals ETF | 3.34 | |||
| AFOS | ARS Focused Opportunities Strategy ETF | 3.33 | |||
| IBRN | iShares Neuroscience and Healthcare ETF | 3.25 | |||
| XPH | SPDR S&P Pharmaceuticals ETF | 3.21 | |||
| CLSE | Convergence Long/Short Equity ETF | 3.19 | |||
| ARKG | ARK Genomic Revolution Multi-Sector ETF | 1.75 |
Loading charts...
How does ARKG fit in your portfolio?
Add your other holdings to see your portfolio's Sharpe Ratio and find out.
Analyze Your Portfolio